Dermatological drugs, topical agents, and cosmetics

Side Effects of Drugs Annual

Volumn 32, Issue , 2010, Pages 295-304

  Duarte, Ida ^a   Lazzarini, Rosana ^a   Rotter, Anita ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857266364     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(10)32014-9     Document Type: Chapter

References (52)

1. Kolbach D.N., Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992, 27(5 Pt 1):769-771.
2. Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P., Wassilew S.W., Horn T., Kreysel H.W., Lutz G. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994, 30(6):977-981.
3. Mrowietz U., Christophers E., Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998, 138(3):456-460.
4. Litjens N.H., van Strijen E., van Gulpen C., Mattie H., van Dissel J.T., Thio H.B., Nibbering P.H. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 2004, 4:22.
5. Nibbering P.H., Thio B., Zomerdijk T.P., Bezemer A.C., Beijersbergen R.L., van Furth R. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 1993, 101(1):37-42.
6. Thio H.B., Zomerdijk T.P., Oudshoorn C., Kempenaar J., Nibbering P.H., van der Schroeff J.G., Ponec M. Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Br J Dermatol 1994, 131(6):856-861.
7. Vandermeeren M., Janssens S., Borgers M., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997, 234(1):19-23.
8. Sebok B., Bonnekoh B., Vetter R., Schneider I., Gollnick H., Mahrle G. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma-induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol 1998, 8(1):29-32.
9. Ockenfels H.M., Schultewolter T., Ockenfels G., Funk R., Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998, 139(3):390-395.
10. Vandermeeren M., Janssens S., Wouters H., Borghmans I., Borgers M., Beyaert R., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001, 116(1):124-130.
11. Weber H.O., Borelli C., Röcken M., Schaller M. Treatment of disseminated granuloma annulare with low-dose fumaric acid. Acta Derm Venereol 2009, 89(3):295-298.
12. Venten I., Hess N., Hirschmüller A., Altmeyer P., Brockmeyer N. Treatment of therapy-resistant alopecia areata with fumaric acid esters. Eur J Med Res 2006, 11(7):300-305.
13. Kreuter A., Knierim C., Stücker M., Pawlak F., Rotterdam S., Altmeyer P., Gambichler T. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br J Dermatol 2005, 153(4):802-807.
14. Coras B., Vogt T.H., Ulrich H., Landthaler M., Hohenleutner U. Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris?. Br J Dermatol 2005, 152(2):388-389.
15. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., Eraksoy M., Meluzinova E., Rektor I., Dawson K.T., Sandrock A.W., O'Neill G.N. BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372(9648):1463-1472.
16. Heinz C., Heiligenhaus A. Improvement of noninfectious uveitis with fumaric acid esters: results of a pilot study. Arch Ophthalmol 2007, 125(4):569-571.
17. Harries M.J., Chalmers R.J., Griffiths C.E. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 2005, 153(3):549-551.
18. Nieboer C., de Hoop D., Langendijk P.N., van Loenen A.C., Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990, 181(1):33-37.
19. Ng S.Y., Wilkinson J. A salutary case of Fumaderm potentially masking the symptoms of bowel cancer and partial bowel obstruction. Br J Dermatol 2007, 157(4):825-826.
20. de Haan P., von Blomberg-van der Flier B.M., de Groot J., Nieboer C., Bruynzeel D.P. The risk of sensibilization and contact urticaria upon topical application of fumaric acid derivatives. Dermatology 1994, 188(2):126-130.
21. Foti C., Zambonin C.G., Cassano N., Aresta A., Damascelli A., Ferrara F., Vena G.A. Occupational allergic contact dermatitis associated with dimethyl fumarate in clothing. Contact Derm 2009, 61(2):122-124.
22. Rantanen T. The cause of the Chinese sofa/chair dermatitis epidemic is likely to be contact allergy to dimethylfumarate, a novel potent contact sensitizer. Br J Dermatol 2008, 159(1):218-221.
23. Morton L.M., Bernstein L., Wang S.S., Hein D.W., Rothman N., Colt J.S., Davis S., Cerhan J.R., Severson R.K., Welch R., Hartge P., Zahm S.H. Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis 2007, 28(12):1759-1764.
24. Katar S., Devecioglu C., Ozbek M.N., Ecer S. Henna causes life-threatening hyperbilirubinaemia in glucose-6-phosphate dehydrogenase deficiency. Clin Exp Dermatol 2006, 32:235-236.
25. Mouzopoulos G., Tsouparopoulos V., Stamatakos M., Mihelarakis I., Pasparakis D., Agapitos E. Cutaneous mercury deposits after henna dye application in the arm. Br J Dermatol 2007, 157(2):394-395.
26. Davies E.E.G., Grabczynska S. Para-phenylenediamine allergy from a henna tattoo. Arch Dis Child 2007, 92(3):243.
27. Corrente S., Moschese V., Chianca M., Graziani S., Iannini R., La Rocca M., Chini L. Temporary henna tattoo is unsafe in atopic children. Acta Paediatr 2007, 96(3):469-471.
28. Gordon M.K., Kraus M., van Besien K. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leuk Lymphoma 2007, 48(4):816-818.
29. Shaw D.W., Maibach H.I., Eichenfield L.F. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. J Am Acad Dermatology 2007, 56(2):342-345.
30. Goksugur N., Ozbostanci B., Goksugur S.B. Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alba. Pediatr Dermatol 2007, 24(5):63-65.
31. Georgala S., Befon A., Maniatopoulou E., Georgala C. Topical use of minoxidil in children and systemic side effects. Dermatology 2007, 214(1):101-102.
32. Callen E.C., Church C.O., Hernandez C.L., Thompson E.D. Stevens-Johnson syndrome associated with oral minoxidil: a case report. J Nephrol 2007, 20(1):91-93.
33. Katrine E.K., Lindeburg K.E.K., Brogaard H.M.V., Jemec G.B.E. Pain and photodynamic therapy (PDT). Dermatology 2007, 215(3):206-208.
34. Harries M.J., Street G., Gilmour E., Rhodes L.E., Beck M.H. Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. Photodermatol Photoimmunol Photomed 2007, 23:35-36.
35. Vos L.E., Vermeer M.H., Pavel S. Acitretin induces capillary leak syndrome in a patient with pustular psoriasis. J Am Acad Dermatol 2007, 56(2):339-342.
36. Arnault J.P., Petitpain N., Granel-Brocard F., Cuny J.F., Barbaud A., Schmutz J.L. Acitretin and sixth nerve palsy. J Eur Acad Dermatol Venereol 2007, 21(9):1258-1259.
37. Bastos P.R., Avelleira J.C.R., Cruz M.A., de Oliveira N.C., Azulay D.R. Granulation tissue in palpebral conjunctivae associated with acitretin therapy. J Am Acad Dermatol 2008, 58(2):S41-S42.
38. Dresden G. Atrial tachycardia associated with isotretinoin use. Arch Dermatol 2007, 143(8):1084-1085.
39. Aydogan K., Karli N. Effects of oral isotretinoin therapy on peripheral nerve functions: a preliminary study. Clin Exp Dermatol 2007, 32(1):81-84.
40. Yaman M., Albayram S., Altintas A., Yeni S.N., Karaagac N., Islak C. A cerebellar demyelinating lesion following treatment of acne with isotretinoin. Clin Exp Dermatol 2008, 33(2):118-121.
41. Laroche M.L., Macian-Montoro F., Merle L., Vallat J.M. Cerebral ischemia probably related to isotretinoin. Ann Pharmacother 2007, 41(6):1073-1076.
42. Taibjee S.M., Charles-Holmes R. Pitfalls of prescribing acne therapies including isotretinoin for pilots. Br J Dermatol 2008, 158(3):653-655.
43. Halpagi P., Grigg J., Klistorner A., Damian D.L. Night blindness following low-dose isotretinoin. J Eur Acad Dermatol Venereol 2008, 22(7):893-894.
44. Martinez-Gonzalez M.C., Garcia-Silva J., Sanchez M.A., Castineiras I., Del Pozo J., Capdevila E.F. Acute myopia while on oral isotretinoin treatment. J Eur Acad Dermatol Venereol 2007, 21(7):977-978.
45. Ozdemir M.A., Kose M., Karakukcu M., Ferahbas A., Patiroglu T., Koklu E. Isotretinoin-induced agranulocytosis. Pediatr Dermatol 2007, 24(4):425-426.
46. Lupi-Pegurier L., Muller-Bolla M., Fontas E., Ortonne J.P. Reduced salivary flow induced by systemic isotretinoin may lead to dental decay. Dermatology 2007, 214(3):221-226.
47. Madan V., Muston H.L., Marsland A.M. Isotretinoin-induced pleuritic chest pain. Br J Dermatol 2007, 157(2):385-386.
48. Eksioglu E., Oztekin F., Unlu E., Cakci A., Keyik B., Karadavut I.K. Sacroiliitis and polyneuropathy during isotretinoin treatment. Clin Exp Dermatol 2008, 33(2):122-124.
49. Kwon H.J., Lee J.Y., Cho B.K., Park H.J. Menstrual irregularity during isotretinoin treatment. J Am Acad Dermatol 2007, 21(4):562-563.
50. Berard A., Azoulay L., Koren G., Blais L., Perreault S., Oraichi D. Isotretinoin pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007, 63(2):196-205.
51. Kircik L.H., Peredo M.I., Bucko A.D., Loss R.W., Fowler J.F., Wortzman M., Neumaier G.J. Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study. Cutis 2008, 82(5):358-366.
52. Knackstedt C., Winograd R., Koch A., Abuzahra F., Trautwein C., Wasmuth H.E. Acute necrotic pancreatitis induced by severe hypercalcaemia due to tacalcitol ointment. Br J Dermatol 2007, 156:575-612.